Improving Buprenorphine Detoxification Outcomes With Isradipine
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This application seeks to address the problem of opioid withdrawal by examining the utility
of the L-type calcium channel blocker (CCB) isradipine as an adjunct to BUP detoxification.
This project will address the need for improved detoxification strategies by assessing the
tolerability and preliminary efficacy of adjunct isradipine during a BUP detoxification in
opioid-dependent participants. This pilot clinical trial will determine the potential utility
of the L-type CCB isradipine to improve treatment outcomes in up to 60 opioid-dependent
individuals undergoing a BUP detoxification procedure. Specifically, this study will
determine the efficacy of isradipine to reduce withdrawal symptoms, craving, and illicit use
of opioids in opioid-dependent individuals undergoing BUP detoxification and determine the
tolerability and safety of controlled-release isradipine (10 mg/day) in opioid-dependent
individuals undergoing BUP detoxification. Currently, the only FDA-approved medications for
opioid withdrawal are the opioid agonists methadone and BUP, both of which have abuse
liability. Our findings, if positive, will support a larger phase II clinical trial.